Hemochromatosis Arthropathy: Whether Phlebotomy Changes the Joint Outcome
A single patient whose hands are the one place his hereditary hemochromatosis has already left a mark. The disagreement isn’t whether phlebotomy is indicated — it clearly is — it’s whether starting it will do anything for the joints already showing damage.
Owen T., a 61-year-old man, spends most afternoons in the workshop behind his house, still building the same style of dovetailed cabinets he sold commercially for twenty years before retiring, work that depends entirely on hands that have started giving him trouble. Eighteen months ago he noticed stiffness in the knuckles closest to his palms — the second and third joints of both hands — worse after a long session at the workbench and slow to loosen up the next morning. X-rays taken three months ago showed early hook-shaped osteophytes at exactly those joints, a distribution his rheumatologist recognized immediately as atypical for ordinary osteoarthritis, which almost never targets the second and third MCP joints this early or this symmetrically.
The workup that followed found a ferritin of 850ng/mL and a transferrin saturation of 68%, both markedly elevated, and genetic testing — prompted by his older brother’s hemochromatosis diagnosis two years ago — confirmed he is homozygous for the HFE C282Y mutation. Everywhere else, the disease has so far spared him: liver enzymes are normal, elastography shows no fibrosis, his cardiac function on echocardiogram is unremarkable, and he has no diabetes. A joint aspirate from his right second MCP, sent to look for calcium pyrophosphate crystals, came back negative this time. The joints, in other words, are the one organ system already showing damage, caught at what looks radiographically like an early stage. Phlebotomy is the undisputed treatment for the iron overload itself, indicated regardless of what happens to his hands. Whether it reaches the hands is the part no one can promise him, and the literature he would be counselled from does not quite describe him: Sahinbegovic et al.’s cross-sectional study of 199 hemochromatosis patients, the largest characterization of this arthropathy, found joint disease frequent, early, and often severe enough to end in joint replacement — but that cohort was, on the whole, considerably further along than a man whose films show hook osteophytes and nothing past them, and it was never built to ask whether treating at his stage changes the trajectory at all. He is asking a question about the earliest end of a disease that has mostly been studied at its later end.
What phlebotomy can and can’t be expected to reach
Start phlebotomy now, regardless of what happens with his hands. Preventing liver, cardiac, and endocrine complications is the dominant, undisputed indication for iron reduction in confirmed hereditary hemochromatosis, and it protects the organs still normal today. A weekly phlebotomy schedule until ferritin reaches target, then maintenance phlebotomy after that.
You’re right that the systemic indication isn’t in question — but “regardless of what happens with his hands” risks him walking out thinking phlebotomy will also fix them, and it usually doesn’t.
Sahinbegovic et al., in Arthritis & Rheumatism in 2010, characterized this arthropathy across 199 hemochromatosis patients and found it frequent, early, and severe enough that a real share of them went on to joint replacement — it is not a footnote to the iron overload. And the older phlebotomy literature, back to Askari’s 1983 series on early venesection, is consistent on the point that actually bears here: once the arthropathy is established, iron depletion does not reliably reverse it, likely reflecting iron-induced chondrocyte toxicity and secondary CPPD deposition that phlebotomy doesn’t directly reach. His joint-directed management — an NSAID now, possibly hand splinting or intra-articular options later — shouldn’t wait months to see whether phlebotomy helps a system it may never meaningfully reach.
I agree with starting both in parallel rather than sequentially — but I’d stop short of telling him the joints definitely won’t respond. The Sahinbegovic cohort describes largely established disease, often diagnosed and treated well after real joint damage had already progressed. His films show hook osteophytes only, no advanced changes — a genuinely earlier stage than that literature specifically isolates.
Whether starting phlebotomy this early, before significant cartilage iron deposition has accumulated, changes his joint trajectory is a real question the existing data don’t clearly answer either way. I’d be honest with him about both parts: established arthropathy typically doesn’t reverse with iron reduction, and separately, we genuinely don’t know yet what early treatment does — then track his symptoms and repeat imaging over the next year to see which answer his own case turns out to give.
Agreed: start weekly phlebotomy to target ferritin today, begin NSAID therapy for his hand symptoms now rather than waiting, and give honest counseling that established hemochromatosis arthropathy often doesn’t improve with iron reduction alone.
Not agreed, and left as a real open branch rather than smoothed over:
State the “early disease might still respond” possibility plainly, as genuine, unresolved uncertainty worth tracking over the next year.
That framing, even carefully qualified, risks the same false reassurance the Sahinbegovic data argues against — even in a patient whose disease looks early today.